The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis-Reference-Cited by-同舟云学术

The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis

Published:2018-01-04 Issue:4 Volume:20 Page:780-791
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Linde Cecilia¹,Cleland John G.F.²,Gold Michael R.³,Claude Daubert J.⁴,Tang Anthony S.L.⁵,Young James B.⁶,Sherfesee Lou⁷,Abraham William T.⁸

Affiliation:

1. Heart and Vascular Theme; Karolinska University Hospital, Stockholm, Sweden; and Karolinska Institutet Stockholm; Sweden

2. Robertson Centre for Biostatistics and Clinical Trials; University of Glasgow and National Heart & Lung Institute; Imperial College London UK

3. Medical University of South Carolina; Charleston SC USA

4. Faculté de Médecine; University of Rennes 1; Rennes France

5. The Island Medical Program; University of British Columbia; Vancouver Canada

6. Cleveland Clinic Lerner College of Medicine; Cleveland OH USA

7. Medtronic plc; Minneapolis MN USA

8. Division of Cardiovascular Medicine and the Davis Heart and Lung Research Institute; The Ohio State University; Columbus Ohio USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Cardiac resynchronization in chronic heart failure;Abraham;N Engl J Med,2002

2. Developed in collaboration with the European Heart Rhythm Association (EHRA);Brignole;Eur Heart J,2013

3. Cardiac Resynchronization-Heart Failure Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure;Cleland;N Engl J Med,2005

4. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial;Daubert;J Am Coll Cardiol,2009

5. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms;Linde;J Am Coll Cardiol,2008

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated B-Type Natriuretic Peptide Level as a Residual Risk Factor for Ventricular Arrhythmias Among Patients Undergoing Cardiac Resynchronization Therapy With Improved Left Ventricular Ejection Fraction;Circulation Reports;2024-09-14

2. Heart Size Difference Drives Sex‐Specific Response to Cardiac Resynchronization Therapy: A Post Hoc Analysis of the MORE‐MPP CRT Trial;Journal of the American Heart Association;2024-06-18

3. Relationship between sex, body size, and cardiac resynchronization therapy benefit: A patient-level meta-analysis of randomized controlled trials;Heart Rhythm;2024-06

4. Clinical utility of QRS duration normalized to left ventricular volume for predicting cardiac resynchronization therapy efficacy in patients with “mid-range” QRS duration;Heart Rhythm;2024-06

5. Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC;European Journal of Heart Failure;2024-05-23